Form 4: Tenaya Therapeutics SVP Sells Shares for Tax

Tenaya Therapeutics' SVP of Finance, Tomohiro Higa, sold common stock to cover tax obligations related to restricted stock unit vesting.

Summary

• Tomohiro Higa, SVP of Finance at Tenaya Therapeutics, Inc. (TNYA), reported sales of common stock on August 18, 2025.
• A total of 523 shares were sold at a weighted average price of $1.253 to cover tax withholding obligations from restricted stock units (RSUs) awarded on February 15, 2023.
• An additional 717 shares were sold at a weighted average price of $1.253 for tax withholding related to RSUs awarded on February 23, 2024.
• Furthermore, 1,722 shares were sold at a weighted average price of $1.253 to cover tax withholding for RSUs awarded on January 24, 2025.
• The sales prices for these transactions ranged from $1.18 to $1.32 per share.
• Following these transactions, Tomohiro Higa beneficially owns 95,338 shares of common stock, which includes 54,220 shares that will be issued upon vesting of restricted stock units.

Sentiment

Score: 5

Explanation: The transaction is a non-discretionary sale to cover tax obligations upon RSU vesting, which is a routine event and does not indicate a change in management's sentiment towards the company's prospects.

Positives

• The vesting of restricted stock units indicates the continued employment and compensation of a key executive, which is generally a positive sign for management stability.
• The company is utilizing equity compensation, aligning executive interests with shareholder value over the long term.

Negatives

• The sales, while for tax purposes, result in a reduction of the executive's direct share ownership.

Future Outlook

N/A

Industry Context

This Form 4 filing details a routine insider transaction for tax purposes, common across all industries, particularly in biotechnology where executive compensation often includes equity awards like Restricted Stock Units (RSUs). Such transactions are a standard part of managing equity compensation.

Stakeholder Impact

• Minimal direct impact on shareholders as these are routine tax-related sales by an executive.
• Employees holding similar RSU awards may see this as a standard process for equity compensation.

Key Dates

Keywords

Tenaya Therapeutics, TNYA, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Tax Withholding, Executive Compensation, Tomohiro Higa, Biotechnology, Pharmaceuticals